Thapsigargin is a non-competitive Enzyme inhibitor of the sarco/endoplasmic reticulum calcium ATPase (SERCA). Structurally, thapsigargin is classified as a guaianolide, and is extracted from a plant, Thapsia garganica. It is a tumor promoter in mammalian cells.
Thapsigargin raises (intracellular) calcium concentration by blocking the ability of the cell to pump calcium into the sarcoplasmic and endoplasmic reticula. Store-depletion can secondarily activate plasma membrane , allowing an influx of calcium into the cytosol. Depletion of ER calcium stores leads to ER stress and activation of the unfolded protein response. Non-resolved ER stress can cumulatively lead to cell death. Prolonged store depletion can protect against ferroptosis via remodeling of ER-synthesized phospholipids.
Thapsigargin treatment and the resulting ER calcium depletion inhibits autophagy independent of the UPR.
Thapsigargin is useful in experimentation examining the impacts of increasing cytosolic calcium concentrations and ER calcium depletion.
A study from the University of Nottingham showed promising results for its use against Covid-19 and other coronavirus.
The biological activity has also attracted research into the total synthesis of thapsigargin. To date, three distinct syntheses have been reported: one by Steven V. Ley, one by Phil Baran., and one by P. Andrew Evans.
Preclinical studies demonstrated that other effects of thapsigargin include suppression of nicotinic acetylcholine receptors activity in neurons of the guinea-pig ileum submucous plexus and rat superior cervical ganglion.
Laboratory studies at the University of Nottingham, using in vitro cell cultures, indicates possible potential as a broad spectrum antiviral, with activity against the COVID-19 virus (SARS-CoV-2), a common cold virus, respiratory syncytial virus (RSV), and the influenza A virus.
<15.Dey. S.; Bajaj, S. O "Promising anticancer drug thapsigargin: A perspective toward the total synthesis" Synthetic communication 2018, 48(1), 1-13/>
|
|